Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia.

The New England journal of medicine - 20 Mar 2014

Senniappan Senthil, Alexandrescu Sanda, Tatevian Nina, Shah Pratik, Arya Ved, Flanagan Sarah, Ellard Sian, Rampling Dyanne, Ashworth Michael, Brown Robert E, Hussain Khalid

Abstract excerpt

Hyperinsulinemic hypoglycemia is the most common cause of severe, persistent neonatal hypoglycemia. The treatment of hyperinsulinemic hypoglycemia that is unresponsive to diazoxide is subtotal pancreatectomy. We examined the effectiveness of the mammalian target of rapamycin (mTOR) inhibitor siro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Congenital Hyperinsulinism
Share to Infant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 24645945
DOI: 10.1056/NEJMoa1310967

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24645945-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia.PMID 24645945Read ↗

Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.Semantic proximity Read ↗

mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic SuccessSemantic proximity Read ↗

Sirolimus therapy for congenital hyperinsulinism in an infant with a novel homozygous KCNJ11 mutation.Semantic proximity Read ↗

Sirolimus therapy in a patient with severe hyperinsulinaemic hypoglycaemia due to a compound heterozygous ABCC8 gene mutation.Semantic proximity Read ↗

Sirolimus in the treatment of three infants with diffuse congenital hyperinsulinism.Semantic proximity Read ↗

Congenital Hyperinsulinism.Semantic proximity Read ↗

Evaluation and management of neonatal onset hyperinsulinemic hypoglycemia: a single neonatal center experience.Semantic proximity Read ↗

Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patientSemantic proximity Read ↗

Practical management of hyperinsulinism in infancy.Semantic proximity Read ↗

Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor.Semantic proximity Read ↗

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.Semantic proximity Read ↗

Clinical features of 52 neonates with hyperinsulinism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.